Patient Safety and Medicine Development

At Johnson & Johnson Innovative Medicine, patient safety is always a priority. Below are key questions and answers about the process for monitoring patient safety *before a medicine is approved* by health authorities.

*The following details safety monitoring in the U.S., where the health authority is the Food and Drug Administration (FDA).

What happens during the medicine development process?

Medicines that are prescribed by licensed healthcare providers (HCPs) have been studied in **clinical trials**—an important process to evaluate and understand benefits and risks to patients.

After we have determined a study medicine is ready to study in humans, **clinical trials are conducted in three key phases**. Each of these three phases is an important step toward understanding how the medicine may be both effective and safe for patients. The process of bringing a medicine to market may take more than 10 years.

Phase I

A study medicine is given to a small number of participants to **EVALUATE SAFETY** of the medicine. This is often done in healthy volunteers (people without any known disease or conditions).

Phase II

DETERMINE EFFECTS of the study medicine on disease or condition being evaluated, and determine what doses seem to be effective and safe for testing in a larger group of patients.

Phase III

COMPARE STUDY MEDICINE with a sugar pill (placebo) or "standard" medicine. These studies are generally much larger and longer in duration than Phase I and II studies.

FDA

At the completion of Phase III, we **SUBMIT APPLICATION for approval to the FDA**.

How does J&J Innovative Medicine help to ensure patient safety during clinical trials?

- **REVIEW side effects** reported by physicians or HCPs, also called adverse events
- **COLLECT & REVIEW adverse events** and take all adverse events seriously
- **SHARE clinical trial safety data** with the FDA, following FDA regulations

What does J&J Innovative Medicine do with the information once the clinical trials are completed?

- Submit collected information to the FDA for review
- If the medicine is approved by the FDA, J&J Innovative Medicine and the FDA then create a medicine label to educate prescribers and patients about safe use as well as common side effects
- Medicine is then available for prescribing to patients

If I have more questions about J&J Innovative Medicine's approach to safety, where can I learn more?

For additional information please visit:
https://www.jnj.com/office-of-the-chief-medical-officer

Johnson & Johnson

www.fda.gov
Individuals depicted are models, for illustrative purposes only.

Patient Safety and Medicine Development

At J&J Innovative Medicine, patient safety is always a priority. Below are key questions and answers about the process for monitoring patient safety after a study medicine is approved by health authorities **and is available for prescription by HCPs**.

*The following details safety monitoring in the U.S., where the health authority is the Food and Drug Administration (FDA).

After a medicine is available to patients by prescription, does J&J Innovative Medicine continue to monitor safety?

Yes. On a continuous basis, J&J Innovative Medicine's dedicated healthcare professionals:

- **COLLECT** information received from patients and HCPs
- **ANALYZE** known events and those not seen in the clinical trials
- **REVIEW** the literature for publications of adverse events
- **EVALUATE** to assess trends as needed
- **COLLABORATE** with internal and external experts, and
- **SHARE** collected information with the FDA

J&J Innovative Medicine follows all FDA regulations for providing post-market safety data.

What happens if J&J Innovative Medicine identifies a problem while the medicine is available?

Depending on the nature of the problem, J&J Innovative Medicine and/or the FDA may:

- **UPDATE** a medicine label and/or patient information to ensure awareness of a potential safety issue or safe use of the product
- **SEND** a letter to communicate important safety information to physicians and HCPs
- **REMOVE** a medicine from the market either temporarily or permanently

Are there more studies after a medicine is available for prescription?

For some medicines, clinical trials continue in the post-marketing setting. These trials are called Phase IV studies.

PHASE IV

J&J Innovative Medicine may decide to voluntarily conduct a Phase IV study, or it may be required by the FDA. These Phase IV clinical trials may study:

- Side effects that may not have been seen in earlier trials
- How well a new treatment works over a long period of time or when used widely

Johnson & Johnson

If I have more questions about J&J Innovative Medicine's approach to safety, where can I learn more?

For additional information please visit:
https://www.jnj.com/office-of-the-chief-medical-officer

www.fda.gov
Individuals depicted are models, for illustrative purposes only.